Clinical Trial Detail

NCT ID NCT02973997
Title Pembrolizumab and Lenvatinib in Treating Metastatic or Recurrent Differentiated Thyroid Cancer That Cannot Be Removed by Surgery
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

thyroid gland follicular carcinoma

thyroid gland cancer

thyroid gland papillary carcinoma

thyroid gland Hurthle cell carcinoma

Therapies

Lenvatinib + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.